Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 14Lymphoma 9Lymphoma, T-Cell 7Lymphoma, Follicular 7Recurrence 6Lymphoma, Non-Hodgkin 6Lymphoma, T-Cell, Peripheral 4Leukemia 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma, B-Cell, Marginal Zone 3Hereditary Sensory and Autonomic Neuropathies 3Hematologic Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Prolymphocytic, T-Cell 2Immunoblastic Lymphadenopathy 2Head and Neck Neoplasms 2Enteropathy-Associated T-Cell Lymphoma 2Sezary Syndrome 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Mycosis Fungoides 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Extranodal NK-T-Cell 1Leukemia, Lymphoid 1Leukemia, Large Granular Lymphocytic 1Hodgkin Disease 1Burkitt Lymphoma 1Advanced Solid Tumors 1

Interventions

Cisplatin 281pembrolizumab 234Radiotherapy 171Cetuximab 169Carboplatin 123Docetaxel 110Paclitaxel 96Fluorouracil 95Nivolumab 88Radiotherapy, Intensity-Modulated 80Magnetic Resonance Spectroscopy 39durvalumab 36Radiation 33Surgical Procedures, Operative 32Drug Therapy 32Biopsy 28Radiosurgery 25Erlotinib Hydrochloride 25Albumin-Bound Paclitaxel 24130-nm albumin-bound paclitaxel 24Taxes 23Specimen Handling 22Platinum 22Immunohistochemistry 21tislelizumab 201,2-diaminocyclohexaneplatinum II citrate 20Cyclophosphamide 19Chemoradiotherapy 19Capecitabine 19tremelimumab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × duvelisib × Clear all
NCT05057247 2025-10-31

Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC

Dana-Farber Cancer Institute

Phase 2 Completed
26 enrolled 23 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04193293 2023-09-21

A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer

SecuraBio

Phase 1/2 Terminated
2 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡